Lördag 24 Januari | 15:47:51 Europe / Stockholm

Prenumeration

Vem äger bolaget?

All ägardata du vill ha finns i Holdings!

2026-01-23 16:30:00

Impala Nordic has interviewed Stian Kildal, CEO of OncoZenge AB (publ), about the recent development of a delayed tranche 3 payment from the Company’s strategic investor and the bridge solution implemented to secure short-term liquidity until the proceeds are received. The Q&A also covers the background of the delay and whether the situation impacts ongoing Phase III preparation activities for BupiZenge, including the current Clinical Trial Application (CTA) process.
 
Read the full interview here.